Article Keywords

On 9 November 2018, the FDA granted accelerated approval to pembrolizumab (Keytruda®, Merck) for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.

KEYNOTE-224

The single-arm, multicentre Keynote-224 (NCT02702414) study enrolled 104 HCC patients with measurable disease and a Child-Pugh Class A score whose disease progressed on or after sorafenib and those intolerant to sorafenib. Among the enrolled patients, 21% were hepatitis B virus (HBV) seropositive, 25% were hepatitis C virus (HCV) seropositive, and 9% were both HBV and HCV seropositive. The study excluded patients with underlying autoimmune disease or those with other conditions requiring immunosuppression, as well as patients with more than one aetiology of hepatitis and patients suspect of having ascites by physical examation. Participants received treatment with pembrolizumab untill progression disease, the onset of an unacceptable toxicity, or study completion after 24 months of treatment.

The primary efficacy endpoint was the overall response rate by independent central review (RECIST 1.1) which measured 17% (95% CI, 11-26); 17 partial and one complete response. The duration of response ranged from 3.1 to 16.7 months. The 6-month response rate (RR) was 89% and the 12-month RR was 56%.

Safety

The toxicity profile of pembrolizumab was conform the United States FDA approved product labeling. In this population there were increased incidences of Grade 3/4 ascites (8%) and immune-related hepatitis (2.9%). Grade 3/4 laboratory abnormalities occurring at higher incidence than reported in other KEYNOTE studies included elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

https://medi-paper.com/wp-content/uploads/2018/09/DRIVER-connects-cancer-patients-in-China-and-the-United-States-to-the-best-care.jpg9941500News Feedhttps://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.pngNews Feed2018-09-07 21:45:362018-09-07 21:45:36DRIVER connects cancer patients in China and the United States to the best care

https://medi-paper.com/wp-content/uploads/2018/05/1526019694_US-FDA-Oncology-Haematology-Drug-Approvals-e1537929700820.jpg10001495News Feedhttps://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.pngNews Feed2018-03-29 14:21:342018-09-25 17:51:10FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

https://medi-paper.com/wp-content/uploads/2018/01/Symposium-Highlight-5HT3-NK1-Palonosetron-Netupitant-CINV-Chemotherapy-induced-Nausea-and-Vomiting-.jpg10001500Stijn van den Borne, MSchttps://medi-paper.com/wp-content/uploads/2018/04/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations-e1523021883812.pngStijn van den Borne, MSc2018-01-30 00:36:322018-04-19 13:57:19Advances in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: From Multi-Dose to Single Dose Control

Cookies and Privacy on medi-paper.com

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Click to enable/disable google analytics tracking.

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.